Abstract
Background: Adipocytokines, adipocyte-secreted hormones, play a critical role in breast cancer development. The expression of visfatin, a newly discovered adipocytokine, in breast cancer tissues was determined and correlated with patient clinicopathologic variables.
Methods: Visfatin expression in breast cancer tissues was analyzed by immunohistochemistry. Visfatin expression was correlated with clinicopathologic variables as well as recurrence rates, using the χ2 test. The prognostic value of visfatin for disease-free and overall survival was evaluated by Kaplan–Meier estimates, and the significance of differences between curves was evaluated by the log-rank test.
Results: High visfatin expression in breast cancer tissues was significantly correlated with tumor size, estrogen receptor (ER) negativity, and progesterone receptor (PR) negativity. Hormone therapy, but not radiotherapy or chemotherapy, decreased the recurrence rate in patients with high visfatin expression. Whereas high visfatin expression alone was associated with poor disease-free and overall survival, worse disease-free and overall survival was observed when high visfatin expression was combined with ER- and PR-negative status. Cox regression analysis also revealed that visfatin is an independent predictor of disease-free and overall survival.
Conclusion: High visfatin expression in breast cancer tissue is associated with more malignant cancer behavior as well as poor patient survival.
Impact: Visfatin is an independent prognosis predictor for breast cancer. Cancer Epidemiol Biomarkers Prev; 20(9); 1892–901. ©2011 AACR.
This article is featured in Highlights of This Issue, p. 1807
Footnotes
Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).
- Received April 29, 2011.
- Revision received June 17, 2011.
- Accepted July 5, 2011.
- ©2011 American Association for Cancer Research.